Jennifer Kehlet Barton

Jennifer Kehlet Barton

Director, BIO5 Institute
Thomas R. Brown Distinguished Chair in Biomedical Engineering
Professor, Agricultural-Biosystems Engineering
Professor, Biomedical Engineering
Professor, Electrical and Computer Engineering
Professor, Medical Imaging
Professor, Optical Sciences
Professor, Cancer Biology - GIDP
Professor, BIO5 Institute
Member of the General Faculty
Member of the Graduate Faculty
Primary Department
Department Affiliations
Contact
(520) 626-0314

Work Summary

I develop new optical imaging devices that can detect cancer at the earliest stage. Optics has the resolution and sensitivity to find these small, curable lesions, and we design the endoscope that provide access to organs inside the body. .

Research Interest

Jennifer Barton, Ph.D. is known for her development of miniature endoscopes that combine multiple optical imaging techniques, particularly optical coherence tomography and fluorescence spectroscopy. She evaluates the suitability of these endoscopic techniques for detecting early cancer development in patients and pre-clinical models. She has a particular interest in the early detection of ovarian cancer, the most deadly gynecological malignancy. Additionally, her research into light-tissue interaction and dynamic optical properties of blood laid the groundwork for a novel therapeutic laser to treat disorders of the skin’s blood vessels. She has published over 100 peer-reviewed journal papers in these research areas. She is currently Professor of Biomedical Engineering, Electrical and Computer Engineering, Optical Sciences, Agriculture-Biosystems Engineering, and Medical Imaging at the University of Arizona. She has served as department head of Biomedical Engineering, Associate Vice President for Research, and is currently Director of the BIO5 Institute, a collaborative research institute dedicated to solving complex biology-based problems affecting humanity. She is a fellow of SPIE – the International Optics Society, and a fellow of the American Institute for Medical and Biological Engineering. Keywords: bioimaging, biomedical optics, biomedical engineering, bioengineering, cancer, endoscopes

Publications

Marion, S. L., Watson, J., Sen, N., Brewer, M. A., Barton, J. K., & Hoyer, P. B. (2013). 7,12-dimethylbenz[a]anthracene-induced malignancies in a mouse model of menopause. Comparative medicine, 63(1), 6-12.

Ovarian cancer has a high mortality rate because there are few symptoms in early disease development. The incidence of ovarian cancer increases in women after menopause. Understanding early events in this disease can best be achieved by using animal models. Therefore, the objective of this study was to develop and track the onset of ovarian tumorigenesis in mice mimicking characteristics of postmenopausal epithelial cancer in women. Female B6C3F1 mice (age, 28 d) received 4-vinylcyclohexene diepoxide (VCD, 160 mg/kg IV daily for 20 d) to cause ovarian failure. Four months after VCD treatment, via surgical intervention, each mouse received a single injection of 7,12-dimethylbenz[a]anthracene (DMBA) or vehicle control (sesame oil) under the bursa of the right ovary to cause ovarian neoplasms. The experimental groups were untreated controls (Con-Con), DMBA-treatment only (Con-DMBA), VCD treatment only (VCD-Con), and VCD+DMBA-treated (VCD+DMBA) mice. At 3, 5, 7, and 9 mo after DMBA injection, ovaries were collected for histologic and immunohistochemical evaluation. No tumors developed in Con-Con mice. All VCD-treated mice (with or without DMBA) exhibited ovarian failure. Mice that received both VCD and DMBA exhibited tumors at 3 mo (50%), 5 mo (14%), 7 mo (90%), and 9 mo (57%) after DMBA treatment; 31% of the tumors were epithelial in origin. Our findings confirm that inducing ovarian tumors in mice by chemical means is an effective method for studying early stages of tumor development that may be relevant to epithelial ovarian cancers that arise in postmenopausal women.

Bonnema, G. T., Cardinal, K. O., Williams, S. K., & Barton, J. K. (2009). A concentric three element radial scanning optical coherence tomography endoscope. JOURNAL OF BIOPHOTONICS, 2(6-7), 353-356.
Vargas, G., Barton, J. K., & Welch, A. J. (2008). Use of hyperosmotic chemical agent to improve the laser treatment of cutaneous vascular lesions. JOURNAL OF BIOMEDICAL OPTICS, 13(2).
Barton, J., Kariya, R., Mathine, D. L., & Barton, J. K. (2004). Analog CMOS circuit design and characterization for optical coherence tomography signal processing. IEEE transactions on bio-medical engineering, 51(12).

We have developed a custom analog CMOS circuit to perform the signal processing for an optical coherence tomography imaging system. The circuit is realized in a 1.5 microm low-noise analog CMOS technology. The circuitry extracts the Doppler frequency from the signal and electrically mixes this with the original signal to provide a filtered A-scan. The circuitry was used to produce a two-dimensional image of an onion.

Zhang, Y., Davidson, B. R., Stamer, W. D., Barton, J. K., Marmorstein, L. Y., & Marmorstein, A. D. (2009). Enhanced inflow and outflow rates despite lower IOP in bestrophin-2-deficient mice. Investigative ophthalmology & visual science, 50(2), 765-70.

Bestrophin-2 (Best2), a putative Cl(-) channel is expressed in the nonpigmented epithelium (NPE). Disruption of Best2 in mice results in a diminished intraocular pressure (IOP). Aqueous humor dynamics were compared in Best2(+/+) and Best2(-/-) mice, to better understand the contribution of Best2 to IOP.